Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia

Lundbeck Australia Pty Ltd

Sunday, 15 October, 2017

Rexulti group 02

October 1st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia. REXULTI works on three neurotransmitter systems: serotonin, dopamine and noradrenaline.1

The efficacy and safety of REXULTI have been demonstrated in two short-term studies and one long-term maintenance trial.1

REXULTI tablets are taken once daily and come in dose strengths of 1 mg, 2 mg, 3 mg and 4 mg with a recommended target dose of 2-4 mg/day.

Lundbeck Australia and Otsuka Australia Pharmaceutical are dedicated to bringing innovative new medicines to Australians with psychiatric disorders.

Please review the REXULTI Approved Product Information before prescribing. Product information is available by calling Lundbeck on 1300 721 277 or click here.

1. REXULTI® Australian Approved Product Information.

Related Sponsored Contents

Miele's PG8582 Washer-Disinfector: A safe solution complying with the relevant market standard ISO EN15883 – 1&2

For more than 50 years, Miele Professional has focused on working closely with doctors, hygiene...

Reducing the risk of surface damage: compatibility is crucial

Healthcare equipment and surfaces may pose a transmission risk if not adequately decontaminated.

Material compatibility and communication remains crucial in the fight to prevent healthcare associated infections

The surface environment presents an important route of transmission for microorganisms; when...

  • All content Copyright © 2018 Westwick-Farrow Pty Ltd